Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Co–Founder Sam Santhosh steps down as Chairman and Group CEO; will remain on Board of Directors. Co–founder Mahesh Pratapneni appointed Group CEO. Dr. Felix Olale appointed Chairman of the Board
This drive will expand access to quality diagnostics and help find the ‘missing millions’ – patients that are suffering from TB but not registered in the healthcare system
A staggering 65% of the TB cases in India are in the 15-45 age group
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
The facility will produce 150 million vaccine doses per year
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
Subscribe To Our Newsletter & Stay Updated
